EVALUATING THE EFFICACY OF ALUMINUM PHOSPHATE FORMULATED L2 BASED HUMAN PAPILLOMA VIRUS VACCINE

Authors

  • CHOZHAVEL RAJANATHAN TM Research Department of Plant Biology and Biotechnology, Loyola College, Chennai-600 034.
  • LAKSHMIKANTH G Shantha Biotechnics Limited, Ranga Reddy Dist., Medchal-501 401, Telangana, India.
  • AGASTIAN P Research Department of Plant Biology and Biotechnology, Loyola College, Chennai-600 034.

Abstract

Objective: Human papilloma virus (HPV) caused cervical cancer the second most common cancer among women worldwide and the most common cancer in developing countries like India. Though, currently type specific prophylactic vaccine have been developed, there is a need for cross protective virus neutralizing vaccine. In this study we have tried to show the multi-epitope vaccine and check the final Alum adjuvant formulated vaccine antibody titer.

Methods: Our study was targeted to analyses the in vivo vaccine efficacy of the aluminum adjuvant formulated recombinant multi epitope antigen with two different grades of aluminum phosphate (pH 5.5 & 6.4). Neutralizing antibody titters against the major neutralizing epitope 17-36 aa region of the N-terminal domain.

Results: The results of this study showed that the final aluminium adjuvant recombinant L2 based multi-epitope vaccine produced antibody against 17-36 peptide one of the proven major virus neutralizing epitope.

Conclusion: L2 based multi-epitope recombinant antigen formulated with aluminium adjuvant can be an low cost, broadly protective HPV vaccine.

Keywords: Human papilloma virus L2, Multi-epitope recombinant vaccine, Aluminum adjuvant.

 

References

Roden R, Wu TC. How will HPV vaccines affect cervical cancer? Nat

Rev Cancer 2006;6(10):753-63.

Schmiedeskamp MR, Kockler DR. Human papillomavirus vaccines.

Ann Pharmacother 2006;40(7-8):1344-52.

Villa LL. Overview of the clinical development and results of a

quadrivalent HPV (types 6, 11, 16, 18) vaccine. Int J Infect Dis

;11 Suppl 2:S17-25.

Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus

L1 major capsid protein self-assembles into virus-like particles that are

highly immunogenic. Proc Natl Acad Sci U S A 1992;89(24):12180-4.

Giroglou T, Sapp M, Lane C, Fligge C, Christensen ND, Streeck

RE, et al. Immunological analyses of human papillomavirus capsids.

Vaccine 2001;19(13-14):1783-93.

Campo MS. Vaccination against papillomavirus in cattle. Clin Dermatol

;15(2):27583.

Christensen ND, Kreider JW, Kan NC, DiAngelo SL. The open reading

frame L2 of cottontail rabbit papillomavirus contains antibody-inducing

neutralizing epitopes. Virology 1991;181(2):572-9.

Embers ME, Budgeon LR, Pickel M, Christensen ND. Protective

immunity to rabbit oral and cutaneous papillomaviruses by

immunization with short peptides of L2, the minor capsid protein.

J Virol 2002;76(19):9798-805.

Lin YL, Borenstein LA, Selvakumar R, Ahmed R, Wettstein FO.

Effective vaccination against papilloma development by immunization

with L1 or L2 structural protein of cottontail rabbit papillomavirus.

Virology 1992;187(2):612-9.

Roden RB, Yutzy WH th, Fallon R, Inglis S, Lowy DR, Schiller JT.

Minor capsid protein of human genital papillomaviruses contains

subdominant, cross-neutralizing epitopes. Virology 2000;270(2):254-7.

Pastrana DV, Gambhira R, Buck CB, Pang YY, Thompson CD,

Culp TD, et al. Cross-neutralization of cutaneous and mucosal

Papillomavirus types with anti-sera to the amino terminus of L2.

Virology 2005;337(2):365-72.

Longworth MS, Laimins LA. Pathogenesis of human papillomaviruses

in differentiating epithelia. Microbiol Mol Biol Rev 2004;68(2):362-72.

Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement

with the Folin phenol reagent. J Biol Chem 1951;193(1):265-75.

Rubio I, Bolchi A, Moretto N, Canali E, Gissmann L, Tommasino M,

et al. Potent anti-HPV immune responses induced by tandem repeats

of the HPV16 L2 (20 -- 38) peptide displayed on bacterial thioredoxin.

Vaccine 2009;27(13):1949-56.

Yamaguchi H, Miyazaki M. Refolding techniques for recovering

biologically active recombinant proteins from inclusion bodies.

Biomolecules 2014;4(1):235-51.

Alphs HH, Gambhira R, Karanam B, Roberts JN, Jagu S, Schiller JT,

et al. Protection against heterologous human papillomavirus challenge by

a synthetic lipopeptide vaccine containing a broadly cross-neutralizing

epitope of L2. Proc Natl Acad Sci U S A 2008;105(15):5850-5.

Conway MJ, Alam S, Christensen ND, Meyers C. Overlapping and

independent structural roles for human papillomavirus type 16 L2

conserved cysteines. Virology 2009;393(2):295-303.

Published

2015-09-01

How to Cite

RAJANATHAN TM, C., L. G, and A. P. “EVALUATING THE EFFICACY OF ALUMINUM PHOSPHATE FORMULATED L2 BASED HUMAN PAPILLOMA VIRUS VACCINE”. Asian Journal of Pharmaceutical and Clinical Research, vol. 8, no. 5, Sept. 2015, pp. 199-01, https://innovareacademics.in/journals/index.php/ajpcr/article/view/7290.

Issue

Section

Original Article(s)